{"id":"https://openalex.org/W4381715310","doi":"https://doi.org/10.1111/1346-8138.16820","title":"Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma","display_name":"Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma","alternate_titles":[],"publication_year":2023,"publication_date":"2023-06-22","ids":{"openalex":"https://openalex.org/W4381715310","doi":"https://doi.org/10.1111/1346-8138.16820","pmid":"https://pubmed.ncbi.nlm.nih.gov/37350027"},"language":"en","primary_location":{"id":"doi:10.1111/1346-8138.16820","doi":"https://doi.org/10.1111/1346-8138.16820","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1346-8138.16820","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.16820","source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4381715310"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.16820","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001893646","display_name":"Naoya Yamazaki","orcid":"https://orcid.org/0000-0002-9638-0428","observed_orcids":["https://orcid.org/0000-0002-9638-0428"]},"institutions":[{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Naoya Yamazaki","raw_affiliation_strings":["Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan"],"raw_orcid":"https://orcid.org/0000-0002-9638-0428","affiliations":[{"raw_affiliation_string":"Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan","institution_ids":["https://openalex.org/I4405285273"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050952919","display_name":"Yoshio Kiyohara","orcid":"https://orcid.org/0000-0001-7335-4617","observed_orcids":["https://orcid.org/0000-0001-7335-4617"]},"institutions":[{"id":"https://openalex.org/I4210088324","display_name":"Shizuoka Cancer Center","ror":"https://ror.org/0042ytd14","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210088324"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshio Kiyohara","raw_affiliation_strings":["Dermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan","institution_ids":["https://openalex.org/I4210088324"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042799216","display_name":"Hisashi Uhara","orcid":"https://orcid.org/0000-0001-5391-3397","observed_orcids":["https://orcid.org/0000-0001-5391-3397"]},"institutions":[{"id":"https://openalex.org/I141882310","display_name":"Sapporo Medical University","ror":"https://ror.org/01h7cca57","country_code":"JP","type":"education","lineage":["https://openalex.org/I141882310"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hisashi Uhara","raw_affiliation_strings":["Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan"],"raw_orcid":"https://orcid.org/0000-0001-5391-3397","affiliations":[{"raw_affiliation_string":"Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan","institution_ids":["https://openalex.org/I141882310"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tetsuya Tsuchida","orcid":"https://orcid.org/0000-0001-6847-8682","observed_orcids":["https://orcid.org/0000-0001-6847-8682"]},"institutions":[{"id":"https://openalex.org/I8588240","display_name":"Saitama Medical University","ror":"https://ror.org/04zb31v77","country_code":"JP","type":"education","lineage":["https://openalex.org/I8588240"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tetsuya Tsuchida","raw_affiliation_strings":["Department of Dermatology, Saitama Medical University, Saitama, Japan"],"raw_orcid":"https://orcid.org/0000-0001-6847-8682","affiliations":[{"raw_affiliation_string":"Department of Dermatology, Saitama Medical University, Saitama, Japan","institution_ids":["https://openalex.org/I8588240"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102280664","display_name":"Ai Yoshida","orcid":"https://orcid.org/0009-0001-3507-3918","observed_orcids":["https://orcid.org/0009-0001-3507-3918"]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ai Yoshida","raw_affiliation_strings":["Patient Safety Japan, Bristol-Myers Squibb K.K., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Patient Safety Japan, Bristol-Myers Squibb K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013684848","display_name":"Takako Yamada","orcid":"https://orcid.org/0000-0002-0181-7093","observed_orcids":["https://orcid.org/0000-0002-0181-7093"]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takako Yamada","raw_affiliation_strings":["Patient Safety Japan, Bristol-Myers Squibb K.K., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Patient Safety Japan, Bristol-Myers Squibb K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066970622","display_name":"Akira Komoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210148404","display_name":"Bristol-Myers Squibb (Japan)","ror":"https://ror.org/04dbmrm19","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210148404"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Komoto","raw_affiliation_strings":["Patient Safety Japan, Bristol-Myers Squibb K.K., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Patient Safety Japan, Bristol-Myers Squibb K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148404"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5001893646"],"corresponding_institution_ids":["https://openalex.org/I4405285273"],"apc_list":{"value":3630,"currency":"USD","value_usd":3630},"apc_paid":{"value":3630,"currency":"USD","value_usd":3630},"fwci":0.4435,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.56686905,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":94},"biblio":{"volume":"50","issue":"9","first_page":"1108","last_page":"1120"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.8690000176429749},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8429999947547913},{"id":"https://openalex.org/keywords/post-marketing-surveillance","display_name":"post-marketing surveillance","score":0.7670000195503235},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.9589999914169312},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9020000100135803},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.6679999828338623},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9990000128746033},{"id":"https://openalex.org/keywords/interstitial-lung-disease","display_name":"interstitial lung disease","score":0.7210000157356262},{"id":"https://openalex.org/keywords/hypophysitis","display_name":"hypophysitis","score":0.8460000157356262},{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.4129999876022339},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.5830000042915344},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.6620000004768372},{"id":"https://openalex.org/keywords/real-world-safety","display_name":"real-world safety","score":0.6769999861717224},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7549999952316284},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.4169999957084656}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.892238199710846},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8900340795516968},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8812335729598999},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.7102278470993042},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6956518888473511},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6308503746986389},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6264183521270752},{"id":"https://openalex.org/C197636746","wikidata":"https://www.wikidata.org/wiki/Q7234359","display_name":"Postmarketing surveillance","level":3,"score":0.6147996783256531},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.4667527973651886},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.45466864109039307},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4435018002986908},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3582072854042053},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1697457730770111},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.08111879229545593}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000095225","descriptor_name":"East Asian People","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000096142","descriptor_name":"Cutaneous Malignant Melanoma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D011358","descriptor_name":"Product Surveillance, Postmarketing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/1346-8138.16820","doi":"https://doi.org/10.1111/1346-8138.16820","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1346-8138.16820","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.16820","source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},{"id":"pmid:37350027","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37350027","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of dermatology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/1346-8138.16820","doi":"https://doi.org/10.1111/1346-8138.16820","is_oa":true,"landing_page_url":"https://doi.org/10.1111/1346-8138.16820","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/1346-8138.16820","source":{"id":"https://openalex.org/S143887118","display_name":"The Journal of Dermatology","issn_l":"0385-2407","issn":["0385-2407","1346-8138"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Dermatology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320327845","display_name":"Ono Pharmaceutical","ror":"https://ror.org/022jefx64"}],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W4381715310.pdf"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1999130958","https://openalex.org/W2111877246","https://openalex.org/W2160834915","https://openalex.org/W2166662937","https://openalex.org/W2460289592","https://openalex.org/W2614467908","https://openalex.org/W2733884328","https://openalex.org/W2746991247","https://openalex.org/W2803577717","https://openalex.org/W2896600825","https://openalex.org/W2901290714","https://openalex.org/W2933878484","https://openalex.org/W2996093895","https://openalex.org/W3030892588","https://openalex.org/W3045615435","https://openalex.org/W3080392435","https://openalex.org/W3097511760","https://openalex.org/W3107738233","https://openalex.org/W3135523592","https://openalex.org/W4211110231","https://openalex.org/W4238423864","https://openalex.org/W4293708029","https://openalex.org/W4307432916","https://openalex.org/W4311358851"],"related_works":["https://openalex.org/W4281400504","https://openalex.org/W4311358851","https://openalex.org/W3045615435","https://openalex.org/W2793007221","https://openalex.org/W2901290714","https://openalex.org/W3033336486","https://openalex.org/W4362602133","https://openalex.org/W3080392435","https://openalex.org/W4375850348","https://openalex.org/W4247006305"],"abstract_inverted_index":{"Although":[0],"malignant":[1,58,97,291],"melanoma":[2,59,98,292],"is":[3,9],"relatively":[4],"rare":[5],"in":[6,17,60,76,86,179,184,194,200,287],"Japan,":[7],"it":[8],"often":[10],"diagnosed":[11],"at":[12],"a":[13,265,313],"later":[14],"stage":[15],"than":[16],"Western":[18],"countries.":[19],"Nivolumab":[20],"and":[21,31,44,54,99,107,126,181,188,196,223,243,254],"ipilimumab":[22,45],"are":[23],"immune":[24],"checkpoint":[25],"inhibitors":[26],"targeting":[27],"programmed":[28],"death":[29,244],"1":[30,274],"cytotoxic":[32],"T-lymphocyte-associated":[33],"protein":[34],"4,":[35],"respectively.":[36,198],"Owing":[37],"to":[38,70,176,275],"their":[39],"complementary":[40],"anticancer":[41],"effects,":[42],"nivolumab":[43],"combination":[46],"therapy":[47],"(N":[48],"+":[49,81,102,119,166,169,285],"I)":[50],"has":[51],"been":[52],"studied":[53],"approved":[55],"for":[56,91,154],"treating":[57],"various":[61],"countries":[62],"including":[63,312],"Japan.":[64,87],"Real-world":[65],"postmarketing":[66,281],"surveillance":[67,282],"was":[68,113,124,134,171],"implemented":[69],"record":[71],"treatment-related":[72],"adverse":[73,177],"events":[74,178],"(TRAEs)":[75],"patients":[77,139,160,202,250,271,288],"treated":[78],"with":[79,240,252,289,299],"N":[80,101,118,165,168,284],"I":[82,103,170,286],"following":[83],"its":[84],"approval":[85],"Patients":[88],"were":[89,152,192,203,228,306],"eligible":[90,153],"registration":[92],"if":[93],"they":[94],"had":[95],"unresectable":[96,290],"started":[100],"between":[104],"September":[105],"2018":[106],"August":[108],"2019.":[109],"The":[110,128],"observation":[111],"period":[112],"13":[114],"weeks":[115],"from":[116],"starting":[117],"I.":[120,167],"Only":[121],"safety":[122,296],"information":[123],"collected":[125],"evaluated.":[127],"final":[129],"case":[130],"report":[131],"form":[132],"lock":[133],"March":[135],"2021.":[136],"Overall,":[137,157,246],"173":[138],"(median":[140],"age,":[141],"66.0":[142],"years;":[143],"performance":[144],"status":[145],"0-1,":[146],"88.4%;":[147],"skin:":[148],"53.2%;":[149],"mucosal:":[150],"32.4%)":[151],"the":[155],"analyses.":[156],"34.1%":[158],"of":[159,164,233,248,256,283,301],"completed":[161],"4":[162],"doses":[163],"discontinued":[172],"by":[173,309],"63.0%":[174],"(due":[175],"67.9%":[180],"disease":[182,221],"progression/death":[183],"22.9%).":[185],"Any":[186],"grade":[187,189],"\u22653":[190],"TRAEs":[191,199,227,260,305],"reported":[193],"73.41%":[195],"52.02%,":[197],"\u226510":[201],"hepatic":[204],"function":[205],"abnormal":[206],"(any":[207],"grade/grade":[208],"\u22653:":[209],"23.12%/13.29%),":[210],"pyrexia":[211],"(10.40%/0.58%),":[212],"diarrhea":[213],"(9.25%/2.89%),":[214],"rash":[215],"(8.67%/0.58%),":[216],"hypophysitis":[217],"(5.78%/5.20%),":[218],"interstitial":[219],"lung":[220],"(5.78%/2.89%),":[222],"liver":[224],"disorder":[225],"(5.78%/4.62%).":[226],"classified":[229],"as":[230,264],"recovered":[231,239,272],"(36.99%":[232],"patients),":[234],"recovering":[235],"(44.51%),":[236],"unrecovered":[237],"(13.29%),":[238],"sequelae":[241],"(2.31%),":[242],"(1.73%).":[245],"24":[247],"34":[249],"(70.59%)":[251],"gastrointestinal-related":[253],"53":[255],"65":[257],"(81.54%)":[258],"liver-related":[259],"received":[261],"treatment,":[262],"such":[263],"steroid":[266],"with/without":[267],"an":[268],"immunosuppressant;":[269],"most":[270],"within":[273],"2":[276],"months.":[277],"In":[278],"conclusion,":[279],"this":[280],"revealed":[293],"no":[294],"new":[295],"concerns":[297],"compared":[298],"results":[300],"prior":[302],"studies.":[303],"Immune-related":[304],"generally":[307],"manageable":[308],"appropriate":[310],"treatment":[311],"steroid.":[314]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4381715310","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2023-06-24T00:00:00"}
